

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1093)

VOLUNTARY ANNOUNCEMENT

HIGHLY SELECTIVE SOS1 INHIBITOR (SYH2038) OBTAINS CLINICAL TRIAL APPROVAL

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that highly selective SOS1 inhibitor (SYH2038) (the “**Product**”), a new Class 1 chemical drug developed by the Group, has obtained approval granted by the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China.

SYH2038 is a highly selective SOS1 inhibitor that inhibits the malignant progression of tumor cells by inhibiting the interaction between KRAS and SOS1 proteins. Currently, there is no product of the same type available in the global market. The indication for this clinical trial approval is advanced solid tumor. In preclinical studies, the Product demonstrated a high efficacy target selectivity, with excellent in vitro and in vivo activities as well as good safety profile, providing a promising clinical development value. A number of patent applications of the Product have been submitted in China and overseas.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 27 November 2023

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.